This study is looking at three different conditions: Tuberous Sclerosis Complex, Sanfilippo syndrome, and Fragile X syndrome. These are genetic conditions that can cause behavioral problems such as irritability, aggression, and other challenging behaviors that affect daily life. The treatment being tested is Epidyolex, which is an oral solution containing cannabidiol (also known as CBD). Participants will also receive an oral solution with beta-carotene as part of the study.
The purpose of this study is to investigate whether CBD is effective in reducing irritability and other behavioral problems in children and adults with these three conditions. The study will look at how CBD affects various aspects of behavior, including symptom severity, quality of life, anxiety, depression, mood, autism symptoms, sensory processing, parental stress, and personal goals. For those who also experience seizures, the study will track seizure frequency. The safety of the treatment will be monitored by recording any side effects and checking liver enzyme levels throughout the study.
The study uses a special design called an N-of-1 series, which means each participant will be studied individually over time. Participants will take the CBD oral solution for up to 24 weeks while maintaining their current medications and treatments stable. During this time, caregivers will complete questionnaires and keep diaries to track behavioral changes and any seizures that occur. The maximum daily dose of CBD will be 25 milligrams per kilogram of body weight. Participants need to be at least 6 years old and must have a caregiver who can provide regular reports about their behavior and well-being.



The Netherlands